Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Voluntarily sign and date an informed consent agreement~2. Be a female ≥18 years of age~3. At Screening visit, have 2 bilateral buttocks with each buttock having:~   1. a score of 3 or 4 (moderate or severe) as reported by the subject (PR-PCSS), and~  2. a score of 3 or 4 (moderate or severe) as reported by the Investigator (CR-PCSS)~4. At Day 1 visit, have 2 bilateral buttocks with each buttock having:~   1. a score of 3 or 4 (moderate or severe) as reported by the subject (PR-PCSS), and~  2. a score of 3 or 4 (moderate or severe) as reported by the Investigator (CR-PCSS)~5. Be willing to apply sunscreen to the buttocks before each exposure to the sun while participating in the study (ie, Screening through end of study)~6. Be judged to be in good health, based upon the results of a medical history, physical examination, and laboratory profile at Screening~7. Have a negative serum pregnancy test at Screening and a negative urine pregnancy test before injection of study drug and be using a stable and effective contraception method (eg, abstinence, intrauterine device \[IUD\], hormonal \[estrogen/progestin\] contraceptives, or double barrier method) for at least 1 menstrual cycle prior to study enrollment and for the duration of the study; or be menopausal defined as 12 months of amenorrhea in the absence of other biological or physiological causes, as determined by the Investigator; or post-menopausal for at least 1 year; or be surgically sterile~8. Be willing and able to cooperate with the requirements of the study~9. Be able to read, complete and understand the patient-reported outcomes rating instruments in English~Exclusion Criteria:~1. Has any of the following systemic conditions:~   1. Coagulation disorder~  2. Evidence or history of malignancy (other than excised basal-cell carcinoma) unless there has been no recurrence in at least 5 years~  3. History of keloidal scarring or abnormal wound healing~  4. Concurrent diseases or conditions that might interfere with the conduct of the study, confound the interpretation of the study results, or endanger the subject's well-being. Any questions about concurrent diseases should be discussed with the Medical Monitor~  5. Evidence of clinically significant abnormalities on physical examination, vital signs, electrocardiogram (ECG), or clinical laboratory values~2. Has any of the following local conditions in the areas to be treated:~   1. History of lower extremity thrombosis or post-thrombosis syndrome~  2. Vascular disorder (eg, varicose veins, telangiectasia) in area to be treated~  3. Inflammation or active infection~  4. Severe skin laxity, flaccidity, and/or sagging~  5. Active cutaneous alteration including rash, eczema, psoriasis, or skin cancer~  6. Has a tattoo and/or a mole located within 2 cm of the site of injection~3. Requires the following concomitant medications before or during participation in the trial:~   a. Anticoagulant or antiplatelet medication or has received anticoagulant or antiplatelet medication (except for ≤150 mg aspirin daily) within 7 days before injection of study drug~4. Has used any of the following for the treatment of EFP on a buttock within the timelines identified below or intends to use any of the following at any time during the course of the study:~   1. Liposuction in a buttock during the 12-month period before injection of study drug~  2. Injections (eg, mesotherapy); radiofrequency device treatments; laser treatment; buttock implant treatment; cryolipolysis; or surgery (including subcision and/or powered subcision) within a buttock during the 12-month period before injection of study drug~  3. Any investigational treatment for EFP on a buttock during the 12-month period before the injection of study drug~  4. Endermologie or similar treatments within a buttock during the 6-month period before injection of study drug~  5. Massage therapy within a buttock during the 3-month period before injection of study drug~  6. Creams (eg, Celluvera™, TriLastin®) and/or home therapies to prevent or mitigate EFP within a buttock during the 2-week period before injection of study drug~5. Is presently nursing or providing breast milk~6. Intends to become pregnant during the study~7. Intends to initiate an intensive sport or exercise program during the study~8. Intends to initiate a weight reduction program during the study~9. Intends to use tanning spray or tanning booths during the study~10. Has received an investigational drug or treatment within 30 days before injection of study drug~11. Has a known systemic allergy to collagenase or any other excipient of study drug~12. Has received any collagenase treatments at any time prior to treatment~13. Was a subject in a previous cellulite clinical trial of CCH: AUX-CC-830, AUX-CC-831, EN3835-102, EN3835-104, EN3835-201, EN3835-202, and/or EN3835-205~14. Any other condition(s) that, in the Investigator's opinion, might indicate the subject to be unsuitable for the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- EN3835 Active (Type: ACTIVE_COMPARATOR): EN3835 0.84mg (Collagenase Clostridium Histolyticum)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete